Clustering of alpha-synuclein on supported lipid bilayers: role of anionic lipid, protein, and divalent ion concentration.

Alpha-synuclein is the major component of Lewy body inclusions found in the brains of patients with Parkinson's disease. Several studies indicate that alpha-synuclein binds to negatively charged phospholipid bilayers. We examined the binding of alpha-synuclein to membranes containing different amounts of negatively charged lipids using supported lipid bilayers, epifluorescence microscopy, fluorescence recovery after photobleaching, and bulk fluorescence techniques. The membranes contained phosphatidylcholine and phosphatidylglycerol. In the absence of protein, these lipids mix uniformly. Our results show that the propensity of alpha-synuclein to cluster on the membrane increases as the concentration of anionic lipid and/or protein increases. Regions on the lipid bilayer where alpha-synuclein is clustered are enriched in phosphatidylglycerol. We also observe divalent metal ions stimulate protein cluster formation, primarily by promoting lipid demixing. The importance of protein structure, lipid demixing, and divalent ions, as well as the physiological implications, will be discussed. Because membrane-bound alpha-synuclein assemblies may play a role in neurotoxicity, it is of interest to determine how membranes can be used to tune the propensity of alpha-synuclein to aggregate.

[1]  Hitoshi Takahashi,et al.  NACP, a presynaptic protein, immunoreactivity in Lewy bodies in Parkinson's disease , 1997, Neuroscience Letters.

[2]  V. Buchman,et al.  Part II: α-synuclein and its molecular pathophysiological role in neurodegenerative disease , 2003, Neuropharmacology.

[3]  V. Uversky,et al.  Conformational behavior and aggregation of alpha-synuclein in organic solvents: modeling the effects of membranes. , 2003, Biochemistry.

[4]  L. Forno,et al.  Neuropathology of Parkinson's Disease , 1996, Journal of neuropathology and experimental neurology.

[5]  V. Uversky,et al.  Conformational properties of the SDS-bound state of alpha-synuclein probed by limited proteolysis: unexpected rigidity of the acidic C-terminal tail. , 2006, Biochemistry.

[6]  H. Vorum,et al.  Ca2+ binding to alpha-synuclein regulates ligand binding and oligomerization. , 2001, The Journal of biological chemistry.

[7]  Seung-Jae Lee,et al.  Membrane-bound α-Synuclein Has a High Aggregation Propensity and the Ability to Seed the Aggregation of the Cytosolic Form* , 2002, The Journal of Biological Chemistry.

[8]  Ralf Langen,et al.  Structure of membrane-bound α-synuclein studied by site-directed spin labeling , 2004 .

[9]  Reinhard Jahn,et al.  A Broken α-Helix in Folded α-Synuclein* , 2003, The Journal of Biological Chemistry.

[10]  H. Kato,et al.  Calcium-triggered membrane interaction of the alpha-synuclein acidic tail. , 2006, Biochemistry.

[11]  S. Pasquaré,et al.  Age-Associated Changes in Central Nervous System Glycerolipid Composition and Metabolism , 2002, Neurochemical Research.

[12]  D. Lynch,et al.  Functional consequences of alpha-synuclein tyrosine nitration: diminished binding to lipid vesicles and increased fibril formation. , 2004, The Journal of biological chemistry.

[13]  A. Verkhratsky,et al.  Parameters of calcium homeostasis in normal neuronal ageing , 2000, Journal of anatomy.

[14]  P. Barton,et al.  Phase behavior of synthetic phosphatidylglycerols and binary mixtures with phosphatidylcholines in the presence and absence of calcium ions. , 1978, Biochemistry.

[15]  S E Ide,et al.  Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. , 1997, Science.

[16]  K. Beyer Mechanistic aspects of Parkinson's disease: alpha-synuclein and the biomembrane. , 2007, Cell biochemistry and biophysics.

[17]  M. Citron,et al.  Both Familial Parkinson’s Disease Mutations Accelerate α-Synuclein Aggregation* , 1999, The Journal of Biological Chemistry.

[18]  J Q Trojanowski,et al.  Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. , 1998, The American journal of pathology.

[19]  S. Scarlata,et al.  Membrane binding and self-association of alpha-synucleins. , 2001, Biochemistry.

[20]  J. Trojanowski,et al.  Synucleins Are Developmentally Expressed, and α-Synuclein Regulates the Size of the Presynaptic Vesicular Pool in Primary Hippocampal Neurons , 2000, The Journal of Neuroscience.

[21]  L. Serpell,et al.  Mutation E46K increases phospholipid binding and assembly into filaments of human alpha-synuclein. , 2004, FEBS letters.

[22]  T. Lazaridis,et al.  Membrane‐bound structure and energetics of α‐synuclein , 2008 .

[23]  Janel O. Johnson,et al.  α-Synuclein Locus Triplication Causes Parkinson's Disease , 2003, Science.

[24]  D. Harries,et al.  Lipid demixing and protein-protein interactions in the adsorption of charged proteins on mixed membranes. , 2000, Biophysical journal.

[25]  D. Leckband,et al.  Structure and dynamics of ion-induced domains in free and supported monolayers and bilayers , 1994 .

[26]  P. S. St George-Hyslop,et al.  α-Synuclein Membrane Interactions and Lipid Specificity* , 2000, The Journal of Biological Chemistry.

[27]  P. Axelsen,et al.  The E46K mutation in alpha-synuclein increases amyloid fibril formation. , 2005, The Journal of biological chemistry.

[28]  D. Eliezer,et al.  A structural and functional role for 11-mer repeats in alpha-synuclein and other exchangeable lipid binding proteins. , 2003, Journal of molecular biology.

[29]  J Q Trojanowski,et al.  A Hydrophobic Stretch of 12 Amino Acid Residues in the Middle of α-Synuclein Is Essential for Filament Assembly* , 2001, The Journal of Biological Chemistry.

[30]  P. Lansbury,et al.  Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[31]  Farzin Haque,et al.  Effect of surface treatment on diffusion and domain formation in supported lipid bilayers. , 2007, Biophysical journal.

[32]  A. Hinderliter,et al.  Domain formation in a fluid mixed lipid bilayer modulated through binding of the C2 protein motif. , 2001, Biochemistry.

[33]  M. L. Schmidt,et al.  α-Synuclein in Lewy bodies , 1997, Nature.

[34]  Jean-Christophe Rochet,et al.  Helical alpha-synuclein forms highly conductive ion channels. , 2007, Biochemistry.

[35]  A. Jonas,et al.  Stabilization of α-Synuclein Secondary Structure upon Binding to Synthetic Membranes* , 1998, The Journal of Biological Chemistry.

[36]  J. Kordower,et al.  Age-associated increases of α-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease? , 2007, Neurobiology of Disease.

[37]  M. Mattson,et al.  Calcium and neurodegeneration , 2007, Aging cell.

[38]  Olaf Riess,et al.  AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease , 1998, Nature Genetics.

[39]  T. Dawson,et al.  Molecular Pathways of Neurodegeneration in Parkinson's Disease , 2003, Science.

[40]  H. Budka,et al.  Nigral burden of α‐synuclein correlates with striatal dopamine deficit , 2008, Movement disorders : official journal of the Movement Disorder Society.

[41]  A. Doig,et al.  A study of the regional effects of alpha-synuclein on the organization and stability of phospholipid bilayers. , 2006, Biochemistry.

[42]  R. Krüger,et al.  Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. , 1998, Nature genetics.

[43]  Min Zhu,et al.  Lipid binding inhibits alpha-synuclein fibril formation. , 2003, The Journal of biological chemistry.

[44]  P. Lansbury,et al.  The impact of the E46K mutation on the properties of alpha-synuclein in its monomeric and oligomeric states. , 2007, Biochemistry.

[45]  R. Crowther,et al.  α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies , 1998 .

[46]  E. Wanker,et al.  Alpha-synuclein selectively binds to anionic phospholipids embedded in liquid-disordered domains. , 2008, Journal of molecular biology.

[47]  S. May,et al.  Domain formation induced by the adsorption of charged proteins on mixed lipid membranes. , 2005, Biophysical journal.

[48]  A. Blume,et al.  The mixing behavior of pseudobinary phosphatidylcholine-phosphatidylglycerol mixtures as a function of pH and chain length , 1997, European Biophysics Journal.

[49]  P. Riekkinen,et al.  Interaction between dopamine and phospholipids. Studies of the substantia nigra in Parkinson disease patients. , 1975, Archives of neurology.

[50]  J. Hovis,et al.  Influence of lipid chemistry on membrane fluidity: tail and headgroup interactions. , 2006, Biophysical journal.

[51]  D. Marsh,et al.  Alpha-synuclein association with phosphatidylglycerol probed by lipid spin labels. , 2003, Biochemistry.

[52]  D. Dickson,et al.  Pathology and Biology of the Lewy Body , 1993, Journal of neuropathology and experimental neurology.

[53]  Richard Paylor,et al.  Synaptic Vesicle Depletion Correlates with Attenuated Synaptic Responses to Prolonged Repetitive Stimulation in Mice Lacking α-Synuclein , 2002, The Journal of Neuroscience.

[54]  A. Sidhu,et al.  α‐Synuclein regulation of the dopaminergic transporter: a possible role in the pathogenesis of Parkinson's disease , 2004 .

[55]  E. Sackmann,et al.  Supported Membranes: Scientific and Practical Applications , 1996, Science.

[56]  J. Hoenicka,et al.  The new mutation, E46K, of α‐synuclein causes parkinson and Lewy body dementia , 2004, Annals of neurology.

[57]  Jeff Kuret,et al.  Rapid anionic micelle-mediated alpha-synuclein fibrillization in vitro. , 2003, The Journal of biological chemistry.

[58]  D. Price,et al.  Stabilization of α-Synuclein Protein with Aging and Familial Parkinson's Disease-Linked A53T Mutation , 2004, The Journal of Neuroscience.

[59]  D. Eliezer,et al.  Helix periodicity, topology, and dynamics of membrane-associated alpha-synuclein. , 2005, Protein science : a publication of the Protein Society.

[60]  V. Uversky,et al.  Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human alpha-synuclein. , 2001, Biochemistry.

[61]  P. Lansbury,et al.  NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. , 1996, Biochemistry.

[62]  K. Wakabayashi,et al.  The cellular pathology of Parkinson's disease , 2001, Neuropathology (Kyoto. 1993).